[REVISION HISTORY]
Sjögren disease research and drug development
1 recorded revision of this situation.
What changed
2026-11-11 19:41 UTC → 2026-11-13 10:36 UTC ·
added
removed
Recent clinical developments regarding Sjögren disease, a chronic autoimmune disorder, have focused on both long-term patient risks and new therapeutic options. Research presented at the American College of Rheumatology annual meeting included a twenty-five year analysis of United States decedents from 1999 through 2024. This study identified disparities in cardiovascular mortality, suggesting that chronic inflammation and metabolic factors increase vascular risks for those with the syndrome. In terms of pharmaceutical progress, several investigational treatments have shown promise. Novartis reported positive long-term data for ianalumab, a monoclonal antibody targeting B-cells, with continued improvements in disease activity through week 108. Additionally, a multicenter trial evaluated the efficacy of the Janus kinase inhibitor baricitinib. Furthering these developments, Amgen announced positive results from its Phase 3 OASIZ-301 trial for dazodalibep. dazodalibep, an experimental CD40L antagonist. The randomized, placebo-controlled study, which targeted moderate to severe Sjögren’s disease, met its primary endpoint endpoints after 48 weeks. Both The 1,500 mg and 3,000 mg dosing regimens significantly dose, administered every four weeks, reduced systemic disease activity and improved patient-reported dryness symptoms by an average of 5.6 points compared to 3.8 points for the placebo group, while also significantly improving patient-reported dryness symptoms. The 3,000 mg regimen, administered every twelve weeks, showed a placebo. 5.2-point reduction in disease activity. Amgen reported that benefits were observable as early as week four and were maintained through week 48. The company intends to present full data at the ACR Convergence 2026 meeting.
Versions
- 2026-11-13 10:36 UTC Sjögren disease research and drug development
- 2026-11-11 19:41 UTC Sjögren disease research and drug development
Select a version to see what changed compared to the one before it.